Clinical Trials Sponsored by CLI Foundation

Total 19548 results

PETHEMA Foundation

Completed

GEM05 for Patients With Multiple Myeloma More Than 65 Years Old

Multiple Myeloma

Spain
Kovacs Foundation

Completed

Modic Changes and Associated Features in Southern European Chronic Low Back Pain Patients (MODIC)

Low Back Pain

Spain
Kovacs Foundation

Terminated

WHODAS-II for Patients With Nonspecific Low Back Pain

Low Back Pain

Spain
Foundation Fader

Completed

Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis

Cutaneous Leishmaniasis

Bolivia
Kessler Foundation

Completed

Evaluation of the Effect of an Ankle Foot Orthoses for Ambulatory Function

Hemiplegia, Spastic

United States
PETHEMA Foundation

Completed

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

Acute Myeloblastic Leukaemia

Spain
PETHEMA Foundation

Completed

LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) (LINFOTARGAM)

HIV Infections | Diffuse Large B Cell Lymphoma

Spain
PETHEMA Foundation

Completed

Antifungal Use in Oncohematological Neutropenic Patients

Invader Fungal Infection

Spain
PETHEMA Foundation

Completed

Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation (MERONEM)

Febrile Neutropenia | Allogenic Blood Stem Cell Transplantation

Spain
PETHEMA Foundation

Completed

Pethema Multiple Myeloma 2000

Multiple Myeloma
PETHEMA Foundation

Completed

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Spain
PETHEMA Foundation

Completed

SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia (FLAG-IDA)

Myelodysplastic Syndrome | Acute Myeloblastic Leukemia

Spain
PETHEMA Foundation

Completed

Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (FLAT)

Acute Myeloid Leukemia

Spain
A.T. Still University of Health Sciences
Osteopathic Heritage Foundations; Brentwood Foundation; Colorado Springs Osteopathic... and other collaborators

Completed

Is Osteopathic Manipulative Treatment (OMT) Beneficial for Elderly Patients Hospitalized With Pneumonia? (MOPSE)

Pneumonia

United States
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
CTI BioPharma

Terminated

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Prostate Cancer

United States
CTI BioPharma

Withdrawn

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NSCLC

United States
CTI BioPharma

Withdrawn

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Non-Hodgkin's Lymphoma

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade

United States
CTI BioPharma

Completed

Phase II CT-2103/Carboplatin in Ovarian Cancer

Ovarian Neoplasm

United States
CTI BioPharma

Withdrawn

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (Hepatic)

Metastatic Cancer

United States
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
CTI BioPharma

Completed

CT-2106 for the Second Line Treatment of Ovarian Cancer

Ovarian Cancer

France, United Kingdom, Italy
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
CTI BioPharma

Completed

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (RAPID)

Diffuse Large-Cell Lymphoma

United States, Germany, Canada, Italy, France
CTI BioPharma

Completed

Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer

Colorectal Cancer

Italy
Stichting TRICALS Foundation
Research Foundation Flanders; Stichting ALS Nederland; Fight MND; MNDA; Thierry Latran... and other collaborators

Recruiting

Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Belgium, Netherlands, United Kingdom, Sweden, Spain, Australia
University of Pittsburgh
The Pittsburgh Foundation; Hillman Foundation; RK Mellon Foundation

Completed

Trauma Services Intervention to Prevent Violence (TSI)

Skin Injury Due to Violence | Gunshot Wound, Contact

United States
Dalhousie University
Li Ka Shing Foundation; PHAC/CIHR Influenza Research Network

Terminated

H1N1 Vaccine in Pregnancy: a Registry for the Fall and Winter of 2009

Vaccine Exposure During Pregnancy

Canada
European Foundation for the Study of Diabetes
Eli Lilly and Company; Chinese Medical Association

Completed

Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA) (DPP-ⅣLADA)

Type 1 Diabetes

China
AO Foundation, AO Spine
Orthopaedic Research Foundation

Completed

The Epidemiology, Process and Outcomes of Spine Oncology (EPOSO) (EPOSO)

Secondary Malignant Neoplasm of Vertebral Column

United States, Canada, Hungary
University of Washington
Kettering Foundation; ZOLL Foundation

Unknown

Remote Ischemic Conditioning to Enhance Resuscitation (RICE) Pilot

Cardiac Arrest

United States
Kessler Foundation
The Craig H. Neilsen Foundation

Unknown

Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes

Skeletal Muscle Hypertrophy | Nervous System | Atrophy, Disuse | Disuse Osteoporosis | Structural; Marker

United States
Cambridge Health Alliance
The Arnold P. Gold Foundation; The Arthur Vining Davis Foundations

Completed

MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (MINDFUL-PC)

Depression | Anxiety | Adjustment Disorder | Stress Related Disorder

United States
ETOP IBCSG Partners Foundation
NSABP Foundation Inc

Completed

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer (CALOR)

Breast Cancer

Spain, United States, Australia, Belgium, Switzerland, Canada, Peru, Netherlands, Hungary, South Africa
Manchester University NHS Foundation Trust
Juvenile Diabetes Research Foundation; British Heart Foundation

Recruiting

Paraoxonase and HDL Qualities in Glycaemia and Inflammation (PON1)

Diabetes Mellitus | Bariatric Surgery Candidate

United Kingdom

Clinical Trials Sponsored by CLI Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations